PL3040075T3 - Steroidy c-19 do hamowania neowaskularyzacji - Google Patents

Steroidy c-19 do hamowania neowaskularyzacji

Info

Publication number
PL3040075T3
PL3040075T3 PL14200543T PL14200543T PL3040075T3 PL 3040075 T3 PL3040075 T3 PL 3040075T3 PL 14200543 T PL14200543 T PL 14200543T PL 14200543 T PL14200543 T PL 14200543T PL 3040075 T3 PL3040075 T3 PL 3040075T3
Authority
PL
Poland
Prior art keywords
steroids
inhibiting neovascularization
neovascularization
inhibiting
Prior art date
Application number
PL14200543T
Other languages
English (en)
Polish (pl)
Inventor
Gerhard Unteregger
Original Assignee
Curadis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadis Gmbh filed Critical Curadis Gmbh
Publication of PL3040075T3 publication Critical patent/PL3040075T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14200543T 2014-12-30 2014-12-30 Steroidy c-19 do hamowania neowaskularyzacji PL3040075T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14200543.8A EP3040075B1 (en) 2014-12-30 2014-12-30 C-19 steroids for inhibiting neovascularization

Publications (1)

Publication Number Publication Date
PL3040075T3 true PL3040075T3 (pl) 2018-03-30

Family

ID=52146363

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14200543T PL3040075T3 (pl) 2014-12-30 2014-12-30 Steroidy c-19 do hamowania neowaskularyzacji

Country Status (17)

Country Link
US (1) US10426785B2 (OSRAM)
EP (2) EP3040075B1 (OSRAM)
JP (1) JP6788592B2 (OSRAM)
KR (1) KR102481553B1 (OSRAM)
CN (2) CN107206010B (OSRAM)
CA (1) CA2972324C (OSRAM)
DK (1) DK3040075T3 (OSRAM)
EA (2) EA202190993A3 (OSRAM)
ES (1) ES2651442T3 (OSRAM)
HR (1) HRP20171875T1 (OSRAM)
HU (1) HUE037698T2 (OSRAM)
NO (1) NO3040075T3 (OSRAM)
PL (1) PL3040075T3 (OSRAM)
PT (1) PT3040075T (OSRAM)
RS (1) RS56621B1 (OSRAM)
SI (1) SI3040075T1 (OSRAM)
WO (1) WO2016107778A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632445A1 (en) * 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
CN114149923B (zh) * 2021-11-19 2024-03-08 大连理工大学 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
EP1756139A4 (en) * 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
ES2547339T3 (es) * 2007-11-13 2015-10-05 Curadis Gmbh Esteroides C-19 para usos terapéuticos específicos
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用

Also Published As

Publication number Publication date
KR102481553B1 (ko) 2022-12-26
CN107206010B (zh) 2021-12-21
NO3040075T3 (OSRAM) 2018-02-10
KR20170100539A (ko) 2017-09-04
EP3215161A1 (en) 2017-09-13
EA039485B1 (ru) 2022-02-01
EA201791209A1 (ru) 2017-11-30
EA202190993A3 (ru) 2021-10-29
US10426785B2 (en) 2019-10-01
JP2018508474A (ja) 2018-03-29
CA2972324A1 (en) 2016-07-07
CN107206010A (zh) 2017-09-26
CA2972324C (en) 2023-09-26
PT3040075T (pt) 2017-12-20
RS56621B1 (sr) 2018-03-30
CN113117089A (zh) 2021-07-16
DK3040075T3 (en) 2017-12-18
EP3040075A1 (en) 2016-07-06
ES2651442T3 (es) 2018-01-26
EA202190993A2 (ru) 2021-08-31
JP6788592B2 (ja) 2020-11-25
US20170360804A1 (en) 2017-12-21
HUE037698T2 (hu) 2018-09-28
EP3040075B1 (en) 2017-09-13
WO2016107778A1 (en) 2016-07-07
SI3040075T1 (en) 2018-04-30
HRP20171875T1 (hr) 2018-01-26

Similar Documents

Publication Publication Date Title
IL279833A (en) Anti-cancer drugs
GB2531928B (en) Image-stitching for dimensioning
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
GB201817189D0 (en) Image-stitching for dimensioning
GB201403489D0 (en) Biomarkers for endometriosis
IL252324A0 (en) Anti-cancer drugs
IL252325A0 (en) Anti-cancer drugs
GB201507781D0 (en) Blending techniques for curve fitting
SG11201609350XA (en) Methods for inhibiting necroptosis
GB201406547D0 (en) Lever
GB201420986D0 (en) Neurodegenerative disorders
IL285700A (en) 21- Hydroxylation of steroids
PT3194670T (pt) Dispositivo sanitário
PL3127759T3 (pl) Powlekana tkanina do poduszki powietrznej
GB201405235D0 (en) Improved plumbing apparatus
HUE043127T2 (hu) Berendezés poszturográfiához
SG10201502212RA (en) Urinal apparatus
GB201407820D0 (en) Polymorphic form
GB201407807D0 (en) Polymorphic form
IL249160A0 (en) Crystal forms of an estrogen receptor modulator
PT3040075T (pt) Esteróides c-19 para inibição da neovascularização
GB2535258B (en) Satellite for central heating or for teleheating
GB201407813D0 (en) Polymorphic form
AP2017009818A0 (en) Saturator